Yaochen Lou

Dr. Yaochen Lou

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YXYu Xue
Yu Xue
YDYouting Dong
Youting Dong
YLYaochen Lou
Yaochen Lou
QLQiaoying Lv
Qiaoying Lv
WSWeiwei Shan
Weiwei Shan
XCXiaojun Chen
Xiaojun Chen
Xue Y, et al. J Gynecol Oncol. 2023 Mar;34:e53. https://doi.org/10.3802/jgo.2023.34.e53

21 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
YLYaochen Lou
Yaochen Lou
JLJiongbo Liao
Jiongbo Liao
WSWeiwei Shan
Weiwei Shan
ZXZhiying Xu
Zhiying Xu
XCXiaojun Chen
Xiaojun Chen
JGJun Guan
Jun Guan
About 10–66% of patients with atypical endometrial hyperplasia diagnosed before surgery (preoperative-AEH) are found to have concurrent endometrial cancer (EC) at definitive hysterectomy, leading to incomplete primary surgery and delayed adjuvant treatment. This study aims to investigate the potential risk factors of concurrent EC in preoperative-AEH patients in a clinical setting with a gynecological pathology review. All patients diagnosed with AEH by endometrial biopsy or curettage that then underwent definitive hysterectomy from January 2016 to December 2019 in a tertiary hospital were retrospectively analyzed. All diagnoses were reviewed by gynecological pathologists. A total of 624 preoperative-AEH patients were included, 30.4% of whom had concurrent EC. In multivariate analysis, postmenopausal status and CA125 ≥ 35 U/mL significantly correlated with concurrent EC (OR = 3.57; 95% CI = 1.80–7.06; OR = 2.15; 95% CI = 1.15–4.03). This risk was remarkably increased in patients with both postmenopausal status and CA125 ≥ 35 U/mL (OR = 16.20; 95% CI = 1.73–151.44). Notably, concurrent EC seemed to occur more frequently in women with postmenopausal time ≥ 5 years (OR = 4.04, 95% CI = 1.80–5.85). In addition, CA125 ≥ 35 U/mL seemed to be an independent risk factor (OR = 5.74; 95% CI = 1.80–18.27) for concurrent intermediate-high-risk EC. Intermediate-high-risk EC was also more commonly seen in preoperative-AEH women with postmenopausal time ≥ 5 years (OR = 5.52, 95% CI = 1.21–25.19, p = 0.027). In conclusion, preoperative-AEH patients with postmenopausal status or elevated level of CA125 might have a high risk of concurrent EC. Adequate pre-surgical evaluation might be suggested for such patients.

21 January 2026 in Digital Health
Verified
Journal Article
Open access
NLNan Liu
Nan Liu
FJfeng jiang
feng jiang
YLYaochen Lou
Yaochen Lou
JGJun Guan
Jun Guan
Objectives: This study aimed to systematically characterize the landscape of artificial intelligence (AI) applications in gynecologic cancers, offering a comprehensive overview of current research trends, influential publications, key contributors, and future research directions. The focus of this study was to provide a quantitative overview of the field's development and trends. Materials and Methods: A structured search was performed in the Web of Science Core Collection to identify original articles on AI use in gynecologic oncology. Two independent reviewers screened and selected studies based on predefined inclusion criteria. Extracted data—including publication trends, author and institutional collaborations, keyword co-occurrence, and citation networks—were analyzed using CiteSpace 6.2.R6 and VOSviewer software. Results: A total of 2544 articles were included for analysis. Research activity showed a notable acceleration after 2019, reaching its highest output in 2024. China and the United States emerged as dominant contributors, with the Chinese Academy of Sciences and Fudan University leading among institutions. Influential authors such as Sala Evis, Tian Jie, and Scambia Giovanni were identified. Major research themes focused on “Radiomics,” “Deep Learning,” “Radiotherapy,” and cancers including cervical, ovarian, and endometrial. Recent emerging topics included “Digital Pathology,” “Personalized Medicine,” and “Tumor Heterogeneity,” signaling a shift toward precision oncology. Conclusions: This bibliometric study delineated the evolving field of AI in gynecologic oncology, highlighting dynamic research fronts and gaps.